المؤلفون: Encinas, Cristina, Hernandez-Rivas, José-Ángel, Oriol, Albert, Rosiñol, Laura, Blanchard, María-Jesús, Bellón, José-María, García-Sanz, Ramón, de la Rubia, Javier, de la Guía, Ana López, Jímenez-Ubieto, Ana, Jarque, Isidro, Iñigo, Belén, Dourdil, Victoria, de Arriba, Felipe, Pérez-Ávila, Clara Cuéllar, Gonzalez, Yolanda, Hernández, Miguel-Teodoro, Bargay, Joan, Granell, Miguel, Rodríguez-Otero, Paula, Silvent, Maialen, Cabrera, Carmen, Rios, Rafael, Alegre, Adrián, Gironella, Mercedes, Gonzalez, Marta-Sonia, Sureda, Anna, Sampol, Antonia, Ocio, Enrique M., Krsnik, Isabel, García, Antonio, García-Mateo, Aránzazu, Soler, Joan-Alfons, Martín, Jesús, Arguiñano, José-María, Mateos, María-Victoria, Bladé, Joan, San-Miguel, Jesús F., Lahuerta, Juan-José, Martínez-López, Joaquín

المصدر: Blood Cancer Journal ; volume 12, issue 4 ; ISSN 2044-5385

مصطلحات موضوعية: Oncology, Hematology

الوصف: Infections remain a common complication in patients with multiple myeloma (MM) and are associated with morbidity and mortality. A risk score to predict the probability of early severe infection could help to identify the patients that would benefit from preventive measures. We undertook a post hoc analysis of infections in four clinical trials from the Spanish Myeloma Group, involving a total of 1347 patients (847 transplant candidates). Regarding the GEM2010 > 65 trial, antibiotic prophylaxis was mandatory, so we excluded it from the final analysis. The incidence of severe infection episodes within the first 6 months was 13.8%, and majority of the patients experiencing the first episode before 4 months (11.1%). 1.2% of patients died because of infections within the first 6 months (1% before 4 months). Variables associated with increased risk of severe infection in the first 4 months included serum albumin ≤30 g/L, ECOG > 1, male sex, and non-IgA type MM. A simple risk score with these variables facilitated the identification of three risk groups with different probabilities of severe infection within the first 4 months: low-risk (score 0–2) 8.2%; intermediate-risk (score 3) 19.2%; and high-risk (score 4) 28.3%. Patients with intermediate/high risk could be candidates for prophylactic antibiotic therapies.

الإتاحة: https://doi.org/10.1038/s41408-022-00652-2Test
https://www.nature.com/articles/s41408-022-00652-2.pdfTest
https://www.nature.com/articles/s41408-022-00652-2Test

المؤلفون: Mosquera Orgueira, Adrian, González Pérez, Marta Sonia, Diaz Arias, Jose, Rosiñol, Laura, Oriol, Albert, Teruel, Ana Isabel, Martinez Lopez, Joaquin, Palomera, Luis, Granell, Miguel, Blanchard, Maria Jesus, de la Rubia, Javier, López de la Guia, Ana, Rios, Rafael, Sureda, Anna, Hernandez, Miguel Teodoro, Bengoechea, Enrique, Calasanz, María José, Gutierrez, Norma, Martin, Maria Luis, Blade, Joan, Lahuerta, Juan-Jose, San Miguel, Jesús, Mateos, Maria Victoria

المصدر: Blood Cancer Journal ; volume 12, issue 4 ; ISSN 2044-5385

مصطلحات موضوعية: Oncology, Hematology

الوصف: The International Staging System (ISS) and the Revised International Staging System (R-ISS) are commonly used prognostic scores in multiple myeloma (MM). These methods have significant gaps, particularly among intermediate-risk groups. The aim of this study was to improve risk stratification in newly diagnosed MM patients using data from three different trials developed by the Spanish Myeloma Group. For this, we applied an unsupervised machine learning clusterization technique on a set of clinical, biochemical and cytogenetic variables, and we identified two novel clusters of patients with significantly different survival. The prognostic precision of this clusterization was superior to those of ISS and R-ISS scores, and appeared to be particularly useful to improve risk stratification among R-ISS 2 patients. Additionally, patients assigned to the low-risk cluster in the GEM05 over 65 years trial had a significant survival benefit when treated with VMP as compared with VTD. In conclusion, we describe a simple prognostic model for newly diagnosed MM whose predictions are independent of the ISS and R-ISS scores. Notably, the model is particularly useful in order to re-classify R-ISS score 2 patients in 2 different prognostic subgroups. The combination of ISS, R-ISS and unsupervised machine learning clusterization brings a promising approximation to improve MM risk stratification.

الإتاحة: https://doi.org/10.1038/s41408-022-00647-zTest
https://www.nature.com/articles/s41408-022-00647-z.pdfTest
https://www.nature.com/articles/s41408-022-00647-zTest

المؤلفون: Lazzari, Lorenzo, Balaguer-Roselló, Aitana, Montoro, Juan, Greco, Raffaella, Hernani, Rafael, Lupo-Stanghellini, Maria Teresa, Villalba, Marta, Giglio, Fabio, Facal, Ana, Lorentino, Francesca, Guerreiro, Manuel, Bruno, Alessandro, Pérez, Ariadna, Xue, Elisabetta, Clerici, Daniela, Piemontese, Simona, Piñana, José Luis, Sanz, Miguel Ángel, Solano, Carlos, de la Rubia, Javier, Ciceri, Fabio, Peccatori, Jacopo, Sanz, Jaime

المصدر: Bone Marrow Transplantation ; volume 57, issue 9, page 1389-1398 ; ISSN 0268-3369 1476-5365

مصطلحات موضوعية: Transplantation, Hematology

الوصف: Post-transplant cyclophosphamide (PTCy) has emerged as a promising graft-versus-host disease (GvHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, no studies have reported the efficacy of a GvHD prophylaxis based on PTCy with sirolimus (Sir-PTCy) in patients with acute myeloid leukemia (AML). In this retrospective study, we analyze the use of sirolimus in combination with PTCy, with or without mycophenolate mofetil (MMF), on 242 consecutive adult patients with AML undergoing a myeloablative first allo-HSCT from different donor types, in three European centers between January 2017 and December 2020. Seventy-seven (32%) patients received allo-HSCT from HLA-matched sibling donor, 101 (42%) from HLA-matched and mismatched unrelated donor, and 64 (26%) from haploidentical donor. Except for neutrophil and platelet engraftment, which was slower in the haploidentical cohort, no significant differences were observed in major transplant outcomes according to donor type in univariate and multivariate analysis. GvHD prophylaxis with Sir-PTCy, with or without MMF, is safe and effective in patients with AML undergoing myeloablative allo-HSCT, resulting in low rates of transplant-related mortality, relapse/progression, and acute and chronic GvHD in all donor settings.

الإتاحة: https://doi.org/10.1038/s41409-022-01725-3Test
https://www.nature.com/articles/s41409-022-01725-3.pdfTest
https://www.nature.com/articles/s41409-022-01725-3Test

المؤلفون: Puig, Noemi, Hernández, Miguel T., Rosiñol, Laura, González, Esther, de Arriba, Felipe, Oriol, Albert, González-Calle, Verónica, Escalante, Fernando, de la Rubia, Javier, Gironella, Mercedes, Ríos, Rafael, García-Sánchez, Ricarda, Arguiñano, José M., Alegre, Adrián, Martín, Jesús, Gutiérrez, Norma. C., Calasanz, María J., Martín, María L., Couto, María del Carmen, Casanova, María, Arnao, Mario, Pérez-Persona, Ernesto, Garzón, Sebastián, González, Marta S., Martín-Sánchez, Guillermo, Ocio, Enrique M., Coleman, Morton, Encinas, Cristina, Vale, Ana M., Teruel, Ana I., Cortés-Rodríguez, María, Paiva, Bruno, Cedena, M. Teresa, San-Miguel, Jesús F., Lahuerta, Juan J., Bladé, Joan, Niesvizky, Ruben, Mateos, María-Victoria

المصدر: Blood Cancer Journal ; volume 11, issue 5 ; ISSN 2044-5385

مصطلحات موضوعية: Oncology, Hematology

الوصف: Although case-control analyses have suggested an additive value with the association of clarithromycin to continuous lenalidomide and dexamethasone (Rd), there are not phase III trials confirming these results. In this phase III trial, 286 patients with MM ineligible for ASCT received Rd with or without clarithromycin until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). With a median follow-up of 19 months (range, 0–54), no significant differences in the median PFS were observed between the two arms (C-Rd 23 months, Rd 29 months; HR 0.783, p = 0.14), despite a higher rate of complete response (CR) or better in the C-Rd group (22.6% vs 14.4%, p = 0.048). The most common G3–4 adverse events were neutropenia [12% vs 19%] and infections [30% vs 25%], similar between the two arms; however, the percentage of toxic deaths was higher in the C-Rd group (36/50 [72%] vs 22/40 [55%], p = 0.09). The addition of clarithromycin to Rd in untreated transplant ineligible MM patients does not improve PFS despite increasing the ≥CR rate due to the higher number of toxic deaths in the C-Rd arm. Side effects related to overexposure to steroids due to its delayed clearance induced by clarithromycin in this elderly population could explain these results. The trial was registered in clinicaltrials.gov with the name GEM-CLARIDEX: Ld vs BiRd and with the following identifier NCT02575144. The full trial protocol can be accessed from ClinicalTrials.gov. This study received financial support from BMS/Celgene.

الإتاحة: https://doi.org/10.1038/s41408-021-00490-8Test
https://www.nature.com/articles/s41408-021-00490-8.pdfTest
https://www.nature.com/articles/s41408-021-00490-8Test

المؤلفون: De la Puerta, Rosalía, Montoro, Juan, Aznar, Carla, Lorenzo, Ignacio, González-Barberá, Eva María, Balaguer-Roselló, Aitana, Guerreiro, Manuel, Domínguez, Lara, Salavert, Miguel, Aguilar, Cristóbal, de la Rubia, Javier, Sanz, Jaime, Gómez, María Dolores, Piñana, José Luis

المصدر: Bone Marrow Transplantation ; volume 56, issue 9, page 2212-2220 ; ISSN 0268-3369 1476-5365

مصطلحات موضوعية: Transplantation, Hematology

الإتاحة: https://doi.org/10.1038/s41409-021-01319-5Test
https://www.nature.com/articles/s41409-021-01319-5.pdfTest
https://www.nature.com/articles/s41409-021-01319-5Test

المؤلفون: Cuenca, Isabel, Alameda, Daniel, Sanchez-Vega, Beatriz, Gomez-Sanchez, David, Alignani, Diego, Lasa, Marta, Onecha, Esther, Lecumberri, Ramon, Prosper, Felipe, Ocio, Enrique M., González, Maria Esther, García de Coca, Alfonso, De La Rubia, Javier, Gironella, Mercedes, Palomera, Luis, Oriol, Albert, Casanova, Maria, Cabañas, Valentin, Taboada, Francisco, Pérez-Montaña, Albert, De Arriba, Felipe, Puig, Noemi, Carreño-Tarragona, Gonzalo, Barrio, Santiago, Enrique de la Puerta, Jose, Ramirez-Payer, Angel, Krsnik, Isabel, Bargay, Juan Jose, Lahuerta, Juan Jose, Mateos, Maria-Victoria, San-Miguel, Jesus F., Paiva, Bruno, Martinez-Lopez, Joaquin

المصدر: Leukemia ; volume 35, issue 1, page 245-249 ; ISSN 0887-6924 1476-5551

مصطلحات موضوعية: Oncology, Cancer Research, Hematology

الإتاحة: https://doi.org/10.1038/s41375-020-0800-6Test
http://www.nature.com/articles/s41375-020-0800-6.pdfTest
http://www.nature.com/articles/s41375-020-0800-6Test

المؤلفون: Casanova, Bonaventura, Jarque, Isidro, Gascón, Francisco, Hernández-Boluda, Juan Carlos, Pérez-Miralles, Francisco, de la Rubia, Javier, Alcalá, Carmen, Sanz, Jaime, Mallada, Javier, Cervelló, Angeles, Navarré, Arantxa, Carcelén-Gadea, María, Boscá, Isabel, Gil-Perotin, Sara, Solano, Carlos, Sanz, Miguel Angel, Coret, Francisco

المصدر: Neurological Sciences ; volume 38, issue 7, page 1213-1221 ; ISSN 1590-1874 1590-3478

مصطلحات موضوعية: Psychiatry and Mental health, Neurology (clinical), Dermatology, General Medicine

الإتاحة: https://doi.org/10.1007/s10072-017-2933-6Test

المؤلفون: del Río-Garma, Julio, Bobillo, Sabela, de la Rubia, Javier, Pascual, Cristina, García-Candel, Faustino, García-Gala, Jose M., Gonzalez, Reyes, Abril, Laura, Vidan, Julia, Gomez, Maria Jesús, Peña, Francisco, Arbona, Cristina, Martín-Sanchez, Jesús, Moreno, Gemma, Romón, Iñigo, Viejo, Aurora, Oliva, Ana, Linares, Mónica, Salinas, Ramón, Pérez, Sonia, Garcia-Erce, Jose A., Pereira, Arturo

المصدر: Annals of Hematology ; volume 101, issue 1, page 59-67 ; ISSN 0939-5555 1432-0584

مصطلحات موضوعية: Hematology, General Medicine

الإتاحة: https://doi.org/10.1007/s00277-021-04685-8Test

المؤلفون: Cejalvo, María José, Bustamante, Gabriela, González, Esther, Vázquez-Álvarez, Judith, García, Ricarda, Ramírez-Payer, Ángel, Pérez-Persona, Ernesto, Abella, Eugenia, Garzón, Sebastián, García, Antoni, Jarque, Isidro, González, Marta Sonia, Sampol, Antonia, Motlló, Cristina, Martí, Josep María, Alcalá, Magdalena, Duro, Rafael, González, Yolanda, Sastre, José Luis, Sarrà, Josep, Lostaunau, Giselle, López, Rocío, de la Rubia, Javier

المساهمون: Celgene, a Bristol Myers Squibb Company

المصدر: Annals of Hematology ; volume 100, issue 7, page 1769-1778 ; ISSN 0939-5555 1432-0584

مصطلحات موضوعية: Hematology, General Medicine

الإتاحة: https://doi.org/10.1007/s00277-021-04529-5Test

المؤلفون: Blanes, M., Lorenzo, J. I., Ribas, P., Jiménez, A., González, J. D., Cejalvo, M. J., Solano, C., Alegre, A., de la Rubia, Javier

المساهمون: Red Temática de Investigación Cooperativa en Cancer, Red de Biobancos Hospitalarios, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación

المصدر: Annals of Hematology ; volume 98, issue 8, page 2013-2015 ; ISSN 0939-5555 1432-0584

مصطلحات موضوعية: Hematology, General Medicine

الإتاحة: https://doi.org/10.1007/s00277-019-03663-5Test